A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman, Michael W. Sill, Katherine Bell-Mcguinn, Carol Aghajanian, Heidi J. Gray, Krishnansu S. Tewari, Steven C. Rubin, Thomas J. Rutherford, John K. Chan, Alice Chen, Elizabeth M. Swisher
Research output: Contribution to journal › Article › peer-review
215Scopus
citations
Fingerprint
Dive into the research topics of 'A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study'. Together they form a unique fingerprint.